Astrana HealthvsGE Vernova

ASTH and GEV stock compared: price, dividend, valuation and results, from SEC filings.

ASTH

Astrana Health Inc.

$32.87

Value $1.8B

+3.36%
ASTH's page

GEV

GE Vernova Inc.

$763.57

Value $206B

-4.93%
GEV's page

Astrana Health (ASTH) has a market value of $1.8B and GE Vernova (GEV) $206B. Over the last year, with dividends, ASTH moved +52.7% and GEV +32.4%. The P/E is 34.4 for ASTH and 19.9 for GEV. Dividend yield: ASTH 0.09%, GEV 0.26%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ASTH$1.8B

    GEV$206B

    GEV is 113 times ASTH

  • Revenue, 12 months

    ASTH$3.9B

    GEV$44.0B

    GEV is 11 times ASTH

  • Net income, 12 months

    ASTH$53M

    GEV$10.4B

    GEV is 195 times ASTH

  • Operating margin

    ASTH3.1%

    GEV6.4%

    3.3 points apart

  • ROIC

    ASTH4.5%

    GEV19.5%

    15.0 points apart

  • P/E

    ASTH34.4

    GEV19.9

    ASTH is 1.7 times GEV

  • Dividend yield

    ASTH0.1%

    GEV0.3%

    0.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ASTH+52.7%

GEV+32.4%

100150200DecFebAprJunAugOct
Returns by period
PeriodASTHWith dividendsGEVWith dividends
1 year since November 14, 2025+52.7%Price +52.7%+32.4%Price +32.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ASTHAstrana HealthGEVGE Vernova

Valuation

ASTHGEV
Valuation
Price$32.87$763.57
Market value$1.8B$206B
Enterprise value (EV)$2.4B$192B
P/E34.419.9
P/E, 5-year median35.0–
P/B2.118.1
EV/EBIT19.567.9
Free cash flow yield5.4%8.3%

Results and growth

ASTHGEV
Results and growth
Revenue, 12 months$3.9B$44.0B
Net income, 12 months$53M$10.4B
Free cash flow, 12 months$99M$17.1B
Earnings per share, 12 months$0.96$38.00
Revenue growth, year on year56.4%9.0%
Revenue growth a year, past+35.9%over 5 years+8.7%over 3 years
EPS growth a year, past-14.5%over 5 years–

Margins and returns on capital

ASTHGEV
Margins and returns on capital
Gross margin11.0%21.7%
Operating margin3.1%6.4%
Net margin1.4%23.5%
ROIC4.5%19.5%
ROE6.6%90.8%

Balance sheet

ASTHGEV
Balance sheet
Cash$396M$16.8B
Total debt$977M$3.7B
Net debt / EBITDA3.2-4.1
Interest cover1.9×–

Dividends and buybacks

ASTHGEV
Dividends and buybacks
Dividend yield0.1%0.3%
Dividend per share, 12 months$0.03$2.00
Dividend growth a year, past––
Buyback yield1.4%1.6%
Shareholder yield1.5%1.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ASTH or GEV

Didn't find what you were looking for?

Ask us
Which is bigger, Astrana Health or GE Vernova?

By market value, GE Vernova ($206B) is about 112.6 times Astrana Health ($1.8B), at today's prices.

How did ASTH and GEV stock do over the last 1 years?

Since November 14, 2025, ASTH's price moved +52.7% and GEV's +32.0%. With dividends: ASTH +52.7% (+52.7% a year), GEV +32.4% (+32.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, ASTH or GEV?

The dividend yield at today's price is 0.09% for Astrana Health and 0.26% for GE Vernova. Over the last twelve months they paid $0.03 and $2.00 per share.

What is the P/E of ASTH and GEV?

At today's price, the P/E is 34.4 for ASTH and 19.9 for GEV. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Astrana Health or GE Vernova?

Over the last twelve months, the net margin was 1.4% for Astrana Health and 23.5% for GE Vernova, and the operating margin 3.1% and 6.4%. Revenue was $3.9B and $44.0B.

Which is the better investment, Astrana Health or GE Vernova?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.